Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Nuvation Bio Inc.
  6. News
  7. Summary
    NUVB   US67080N1019

NUVATION BIO INC.

(NUVB)
  Report
Delayed Nyse  -  05/27 04:00:02 pm EDT
3.530 USD   +1.73%
05/11RBC Cuts Price Target on Nuvation Bio to $14 From $15, Maintains Outperform Rating, Speculative Risk Qualifier
MT
05/10Wedbush Adjusts Nuvation Bio Price Target to $17 From $23, Maintains Outperform Rating
MT
05/09Nuvation Bio Reports First Quarter 2022 Financial Results and Provides Business Update
BU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Health Care Stocks Advance Premarket Thursday

01/20/2022 | 09:12am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ARGENX SE 2.25% 300.3 Real-time Quote.-4.76%
NASDAQ COMP. 3.33% 12131.13 Real-time Quote.-22.46%
NOVAVAX, INC. 17.46% 55.29 Delayed Quote.-61.35%
NUVATION BIO INC. 1.73% 3.53 Delayed Quote.-58.47%
All news about NUVATION BIO INC.
05/11RBC Cuts Price Target on Nuvation Bio to $14 From $15, Maintains Outperform Rating, Spe..
MT
05/10Wedbush Adjusts Nuvation Bio Price Target to $17 From $23, Maintains Outperform Rating
MT
05/09Nuvation Bio Reports First Quarter 2022 Financial Results and Provides Business Update
BU
05/09Nuvation Bio Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/04HC Wainwright Starts Nuvation Bio at Buy With $14 Price Target
MT
03/22BMO Capital Adjusts Nuvation Bio's Price Target to $12 From $17, Keeps Outperform Ratin..
MT
02/28NUVATION BIO : Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Bu..
PU
02/28Nuvation Bio Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 20..
CI
02/28Nuvation Bio Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
02/28Nuvation Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides B..
BU
More news
Analyst Recommendations on NUVATION BIO INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -116 M - -
Net Debt 2022 - - -
P/E ratio 2022 -6,58x
Yield 2022 -
Capitalization 770 M 770 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees 68
Free-Float 72,3%
Chart NUVATION BIO INC.
Duration : Period :
Nuvation Bio Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NUVATION BIO INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 3,53 $
Average target price 14,67 $
Spread / Average Target 315%
EPS Revisions
Managers and Directors
David T. Hung President, CEO & Director
Jennifer Fox Chief Financial Officer
Daniel G. Welch Chairman
Gary Hattersley Chief Scientific Officer
Robert B. Bazemore Independent Director
Sector and Competitors
1st jan.Capi. (M$)
NUVATION BIO INC.-58.47%770
MODERNA, INC.-41.86%58 733
LONZA GROUP AG-24.79%44 437
IQVIA HOLDINGS INC.-21.85%41 736
SEAGEN INC.-8.54%26 026
ICON PUBLIC LIMITED COMPANY-26.61%18 478